Incyte (INCY) Total Debt Growth (1y) (2016 - 2026)
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Debt Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - | - |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - | - |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn | 5.94% |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - | 103.99% |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn | - |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn | 0.07% |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn | - |
| 10 | Incyte | 19.28 Bn | 15.27 Bn | 1.17 Bn | -5.59% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -5.59% |
| Dec 31, 2025 | 4.86% |
| Sep 30, 2025 | 13.11% |
| Jun 30, 2025 | 26.07% |
| Mar 31, 2025 | 12.26% |
| Dec 31, 2024 | 2.12% |
| Sep 30, 2024 | 9.56% |
| Jun 30, 2024 | -0.94% |
| Mar 31, 2024 | -0.02% |
| Dec 31, 2023 | 5.16% |
| Sep 30, 2023 | 7.69% |
| Jun 30, 2023 | 1.61% |
| Mar 31, 2023 | -1.86% |
| Dec 31, 2022 | -1.26% |
| Sep 30, 2022 | -10.55% |
| Jun 30, 2022 | -7.68% |
| Mar 31, 2022 | -5.09% |
| Dec 31, 2021 | -3.63% |
| Sep 30, 2021 | -2.13% |
| Jun 30, 2021 | 115.12% |
| Mar 31, 2021 | 115.43% |
| Dec 31, 2020 | 12.80% |
| Jun 30, 2020 | -48.26% |
| Mar 31, 2020 | -45.90% |
| Dec 31, 2019 | 6.91% |
| Jun 30, 2019 | 375.63% |
| Mar 31, 2019 | 21.52% |
| Dec 31, 2018 | 330.73% |
| Sep 30, 2018 | -68.57% |
| Jun 30, 2018 | -66.84% |
| Mar 31, 2018 | 30.88% |
| Dec 31, 2017 | -62.16% |
| Sep 30, 2017 | 36.27% |
| Jun 30, 2017 | 28.78% |
| Sep 30, 2016 | 356,980.00% |
| Jun 30, 2016 | -58.81% |